Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Oct 5, 2021Two-year data demonstrate continued high rates of primary patency including in patients with complex lesionsToday, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...
-
Oct 4, 2021
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2021 on Wednesday, October...
-
Sep 21, 2021Company to add mechanical thrombectomy platform to peripheral interventions portfolio
Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free...
Sep 20, 2021EPOCH trial represents the first positive phase 3 study for selective internal radiation therapyBoston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints,...
-
Sep 9, 2021Company leaders will present long-range strategy and financial goals in addition to market overviews and pipeline updates
Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 22, 2021, from 8:30...
-
Sep 1, 2021
Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based...
-
Aug 10, 2021
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model B Single-Use Bronchoscope, designed for use in bedside...
Aug 4, 2021Study is first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for treatment of pulmonary embolismBoston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and...
-
Aug 2, 2021New Technology Add-on Payment can increase patient access to ERCP procedures with reduced infection risks
Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for single-use duodenoscopes, applicable to the...
-
Jul 27, 2021
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational1 basis...